. Author manuscript; available in PMC: 2021 Jun 2.

Published in final edited form as: Ann Allergy Asthma Immunol. 2020 May;124(5):424–440.e17. doi: 10.1016/j.anai.2020.03.021

Table 15.

Summary of Findings for PICO Question 12^a

Montelukast compared to placebo for management of EoE
Outcomes and follow-up	No. of participants (studies)⁸⁷	Certainty of the evidence (GRADE)	Relative effect, RR (95% CI)	Anticipated absolute effects
Outcomes and follow-up	No. of participants (studies)⁸⁷	Certainty of the evidence (GRADE)	Relative effect, RR (95% CI)	Risk with placebo	Risk difference with montelukast
Solid food dysphagia (improvement) (telephone symptom questionnaire)^b follow-up: 26 wk	41 (1 RCT)	⊕◯◯◯ VERY LOW^c,d	0.79 (0.51–1.21)	760 per 1000	160 fewer per 1000 (370 fewer to 160 more)

The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

The abridged dysphagia questionnaire used the questions on dysphagia frequency, severity, and food impaction from the Mayo Dysphagia Questionnaire, 2-week version.

All patients had first achieved remission with topical glucocorticosteroid treatment. Therefore, this is indirect to our PICO question of should we use montelukast for EoE as the question is very specific to should we use montelukast to maintain remission.

Large CI that crosses 1; estimate based on a single RCT.